Cornerstone Therapeutics (NASDAQ:CRTX)

Critical Therapeutics, Inc. is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to ZYFLO, which is marketed in the United States for the prevention and chronic treatment of asthma in patients twelve years of age and older. Critical Therapeutics is working to expand its zileuton franchise by introducing a twice daily, controlled-release formulation for the prevention and chronic treatment of asthma and an intravenous formulation for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is collaborating with MedImmune, Inc. to design antibody therapies that treat acute and chronic diseases triggered by the inflammatory cytokine HMGB1. Research pipeline programs include lifecycle management to extend the zileuton franchise and an alpha-seven project for the treatment of inflammation. Critical Therapeutics is located in Lexington, Mass

Web site: http://www.crtx.com

Last updated July 30, 2008